However, unlike lung cancer, the mutation and expression status of EGFR correlated with better overall survival in MPM patients, which may explain why the Phase II clinical trials of Erlotinib and Gefitinib, the first generation EGFR tyrosine kinase inhibitors (EGFR-TKIs), did not yield significant responses [99,100]. This evidence concerns the gene EGFR and lung carcinoma.